Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer

Cañada, José Manuel Baena; Gámez-Casado, Salvador; Rodríguez-Pérez, Lourdes; Bandera-López, Cristina; Mesas-Ruiz, Andrés; Campini-Bermejo, Alicia; Bernal-Gómez, Marta; Zalabardo-Aguilar, Manuel; Calvete-Candenas, Julio; Martínez-Bernal, Gala; Quílez-Cutillas, Alicia; Atienza-Cuevas, Lidia; García-Rojo, Marcial; Benítez‐Rodríguez, Encarnación; Pajares-Hachero, Bella; Bermejo-Pérez, María José

doi:10.1016/j.medcle.2021.11.015

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low representation of HER2 (6.30%) and basal (7.30%) tumors also did not develop metastases. As has been shown before, patients with tumors smaller than 1 cm, with luminal A, HER2, and triple-negative subtypes on immunohistochemistry did not develop metastases [13].…”

Section: Discussionsupporting

confidence: 77%

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Gámez-Casado,

Rodríguez-Pérez,

Bandera-López

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Background. Implementing mammogram screening means that clinicians are seeing many breast cancers that will never develop metastases. The purpose of this study was to identify subgroups of breast cancer patients who did not present events related to long-term breast cancer mortality, taking into account diagnosis at breast screening, absence of palpability and axillary involvement, and genomic analysis with PAM50. Patients and Methods. To identify them, a retrospective observational study was carried out selecting patients without any palpable tumor and without axillary involvement, and a genomic analysis was performed with PAM50. Results. The probability of distant metastasis-free interval (DMFI) of 337 patients was 0.92 (95% CI, 0.90–0.93) at 20 years and 0.96 (95% CI, 0.92–1.00) in 95 patients (28%) with available PAM50 tests. In 22 (23.15%) luminal A tumors and in 9 (9.47%) luminal B tumors smaller than 1 cm, and in HER2 and basal type tumors, there were no metastatic events (20-year DMFI of 1.00). Conclusion. Patients with nonpalpable breast cancer found at screening with negative nodes are at very low risk. It is possible to identify subgroups without metastatic events by determining the intrinsic subtype and tumor size less than 1 cm. Therefore, de-escalation of treatment should be considered.

show abstract

Section: Discussionsupporting

confidence: 77%

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Gámez-Casado,

Rodríguez-Pérez,

Bandera-López

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Gámez-Casado,

Rodríguez-Pérez,

Bandera-López

et al. 2024

Preprint

View full text Add to dashboard Cite

Background. Implementing mammogram screening means that clinicians are seeing many breast cancers that will never develop metastases. The purpose of this study was to identify subgroups of breast cancer patients who did not present events related to long-term breast cancer mortality, taking into account diagnosis at breast screening, absence of palpability and axillary involvement, and genomic analysis with PAM50. Patients and Methods. To identify them, a retrospective observational study was carried out selecting patients without palpable tumour, without axillary involvement, and a genomic analysis was performed with PAM50. Results. The probability of distant metastasis-free interval (DMFI) of 337 patients was 0.92 (95% CI, 0.90-0.93) at 20 years and 0.96 (95% CI, 0.92-1.00) in 95 patients (28%) with available PAM50 tests. In 22 (23.15%) luminal A tumours and in 9 (9.47%) luminal B tumours smaller than 1 cm and in HER2 and basal type tumours there were no metastatic events (20-year DMFI of 1.00). Conclusion. Patients with nonpalpable breast cancer found at screening with negative nodes are at very low risk. It is possible to identify subgroups without metastatic events by determining the intrinsic subtype and tumour size less than 1 cm. De-escalation of treatment should be considered.

show abstract

Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer

Cited by 2 publications

References 25 publications

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

Contact Info

Product

Resources

About